53 studies found for: Open Studies | "Oropharyngeal Neoplasms"
Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma.
|2||Not yet recruiting||
Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study
A Post-Market Clinical Trial for Access and Visualization of the Oropharynx and Hypopharynx During Transoral Procedures
Post Operative Adjuvant Therapy De-intensification Trial for Human Papillomavirus-related, p16+ Oropharynx Cancer
Analgesia of Fibula Free Flap Donor Site by Peri-Neuronal Catheter in Oro-Pharyngeal Carcinoma Surgery
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
Swallowing, Speech and Quality of Life of Patients With Carcinoma of the Oropharynx
Establishing Lymphedema and Fibrosis Measures in Oral Cancer Patients
Improving Trans-oral Surgical Outcomes Through Intra-operative Image Guidance
HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA
NBI to Characterize Patterns of Vascular Supply Within Lymphoepithelial Mucosa in Oropharyngeal Cancer
T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
A Pilot Study at a Single-Institution of Pregabalin in the Management of Mucositis Pain in Patients Undergoing Chemoradiation Therapy to the Head and Neck.
Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer
Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer
Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer
Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma
|19||Not yet recruiting||
Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)
Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer
† Indicates status has not been verified in more than two years